Clinical trials are entering an era of unprecedented and increasing complexities, driven by decentralized models, rapidly evolving industry regulations, and globalized execution demands.
The surge in advanced modalities, therapeutic diversity, and expanded global trial reach demands specialized expertise that few organizations can maintain internally. Additionally, talent shortages, rapid fluctuations in the drug development pipeline, and geographic diversification make traditional resourcing models unsustainable.
LabConnect expert Amanda Heller, Senior Director of FSP Solutions, outlines 7 trends redefining today’s Functional Service Provider (FSP) models, to help sponsors overcome these challenges and remain competitive in the race for first-in-class and best-in-class therapies.
Complete the form to download your copy now.
Download Now
Healthcare Interoperability Solutions Market Trends and Size
Revolutionizing clinical trials: the role of AI in accelerating medical breakthroughs - PMC
Healthcare Regulatory Affairs Outsourcing Market توقعات 2034 | الاتجاهات الرئيسية ومحركات النمو
Inspection readiness from the top down
M11 Template: Clinical Electronic Structured Harmonised Protocol (CeSHarP) | FDA
ICH Guideline for GCP 36(R3) Annex 2
How hybrid models and tech are shaping the future of clinical research - Clinical Trials Arena
Conducting Clinical Trials With Decentralized Elements | FDA
Navigating the eClinical Ecosystem: Clarifying the Alphabet Soup
Extension of the IVDR Transitional Periods
FDA’s Final Rule on Laboratory-Developed Tests: Lab Compliance
The New FDA Era Of Radical Transparency And Pervasive Oversight